Ideaya partners with Gilead; Lilly extends offer for Point; Theseus lets go of CEO, CMO

Ideaya and Gilead will study a potential combo in bladder cancer. The South San Francisco-based company announced Monday that it plans to test its MAT2A inhibitor in combination with Gilead’s Trodelvy in MTAP-deletion bladder cancer. Financial terms of the agreement were not disclosed.

Eli Lilly Click here to view original post